|
|
News Breaks | | | | January 3, 2013 | | 05:22 EDT |  | TROV | Trovagene to study transrenal BRAF mutations in primary and metastatic cancers
Trovagene announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's proprietary transrenal DNA, or TrDNA, detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status. | |
|
News For TROV From The Last 14 Days Check below for free stories on TROV the last two weeks. |
|
|
| May 14, 2013 | | 15:55 EDT |  | TROV | Trovagene reports Q1 EPS (7c), two estimates (10c)
Reports Q1 revenue $119,000, two estimates $130,000. Company says the decrease in net loss is primarily due to a change in the fair market value of derivative instruments, which was offset by increased operating expenses during Q1 as compared to the prior year period. | |
|
|
|
|
|
|
